Computed Tomography (CT) Perfusion as an Early Predictive Marker for Treatment Response to Neoadjuvant Chemotherapy in Gastroesophageal Junction Cancer and Gastric Cancer - A Prospective Study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Computed Tomography (CT) Perfusion as an Early Predictive Marker for Treatment Response to Neoadjuvant Chemotherapy in Gastroesophageal Junction Cancer and Gastric Cancer - A Prospective Study. / Lundsgaard Hansen, Martin; Fallentin, Eva; Lauridsen, Carsten; Law, Ian; Federspiel, Birgitte; Bæksgaard, Lene; Svendsen, Lars Bo; Nielsen, Michael Bachmann.

In: PLOS ONE, Vol. 9, No. 5, e97605, 2014, p. 1-10.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Lundsgaard Hansen, M, Fallentin, E, Lauridsen, C, Law, I, Federspiel, B, Bæksgaard, L, Svendsen, LB & Nielsen, MB 2014, 'Computed Tomography (CT) Perfusion as an Early Predictive Marker for Treatment Response to Neoadjuvant Chemotherapy in Gastroesophageal Junction Cancer and Gastric Cancer - A Prospective Study', PLOS ONE, vol. 9, no. 5, e97605, pp. 1-10. https://doi.org/10.1371/journal.pone.0097605

APA

Lundsgaard Hansen, M., Fallentin, E., Lauridsen, C., Law, I., Federspiel, B., Bæksgaard, L., Svendsen, L. B., & Nielsen, M. B. (2014). Computed Tomography (CT) Perfusion as an Early Predictive Marker for Treatment Response to Neoadjuvant Chemotherapy in Gastroesophageal Junction Cancer and Gastric Cancer - A Prospective Study. PLOS ONE, 9(5), 1-10. [e97605]. https://doi.org/10.1371/journal.pone.0097605

Vancouver

Lundsgaard Hansen M, Fallentin E, Lauridsen C, Law I, Federspiel B, Bæksgaard L et al. Computed Tomography (CT) Perfusion as an Early Predictive Marker for Treatment Response to Neoadjuvant Chemotherapy in Gastroesophageal Junction Cancer and Gastric Cancer - A Prospective Study. PLOS ONE. 2014;9(5):1-10. e97605. https://doi.org/10.1371/journal.pone.0097605

Author

Lundsgaard Hansen, Martin ; Fallentin, Eva ; Lauridsen, Carsten ; Law, Ian ; Federspiel, Birgitte ; Bæksgaard, Lene ; Svendsen, Lars Bo ; Nielsen, Michael Bachmann. / Computed Tomography (CT) Perfusion as an Early Predictive Marker for Treatment Response to Neoadjuvant Chemotherapy in Gastroesophageal Junction Cancer and Gastric Cancer - A Prospective Study. In: PLOS ONE. 2014 ; Vol. 9, No. 5. pp. 1-10.

Bibtex

@article{e4bf138944aa4964bc43f57318e0c9ae,
title = "Computed Tomography (CT) Perfusion as an Early Predictive Marker for Treatment Response to Neoadjuvant Chemotherapy in Gastroesophageal Junction Cancer and Gastric Cancer - A Prospective Study",
abstract = "OBJECTIVES: To evaluate whether early reductions in CT perfusion parameters predict response to pre-operative chemotherapy prior to surgery for gastroesophageal junction (GEJ) and gastric cancer.MATERIALS AND METHODS: Twenty-eight patients with adenocarcinoma of the gastro-esophageal junction (GEJ) and stomach were included. Patients received three series of chemotherapy before surgery, each consisting of a 3-week cycle of intravenous epirubicin, cisplatin or oxaliplatin, concomitant with capecitabine peroral. The patients were evaluated with a CT perfusion scan prior to, after the first series of, and after three series of chemotherapy. The CT perfusion scans were performed using a 320-detector row scanner. Tumour volume and perfusion parameters (arterial flow, blood volume and permeability) were computed on a dedicated workstation with a consensus between two radiologists. Response to chemotherapy was evaluated by two measures. Clinical response was defined as a tumour size reduction of more than 50%. Histological response was evaluated based on residual tumour cells in the surgical specimen using the standardized Mandard Score 1 to 5, in which values of 1 and 2 were classified as responders, and 3 to 5 were classified as nonresponders.RESULTS: A decrease in tumour permeability after one series of chemotherapy was positively correlated with clinical response after three series of chemotherapy. Significant changes in permeability and tumour volume were apparent after three series of chemotherapy in both clinical and histological responders. A cut-off value of more than 25% reduction in tumour permeability yielded a sensitivity of 69% and a specificity of 58% for predicting clinical response.CONCLUSION: Early decrease in permeability is correlated with the likelihood of clinical response to pre-operative chemotherapy in GEJ and gastric cancer. As a single diagnostic test, CT Perfusion only has moderate sensitivity and specificity in response assessment of pre-operative chemotherapy making it insufficient for clinical decision purposes.",
keywords = "Adenocarcinoma, Adult, Aged, Esophagogastric Junction, Female, Humans, Male, Middle Aged, Neoadjuvant Therapy, Prospective Studies, Stomach Neoplasms, Tomography, X-Ray Computed, Tumor Markers, Biological",
author = "{Lundsgaard Hansen}, Martin and Eva Fallentin and Carsten Lauridsen and Ian Law and Birgitte Federspiel and Lene B{\ae}ksgaard and Svendsen, {Lars Bo} and Nielsen, {Michael Bachmann}",
year = "2014",
doi = "10.1371/journal.pone.0097605",
language = "English",
volume = "9",
pages = "1--10",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

RIS

TY - JOUR

T1 - Computed Tomography (CT) Perfusion as an Early Predictive Marker for Treatment Response to Neoadjuvant Chemotherapy in Gastroesophageal Junction Cancer and Gastric Cancer - A Prospective Study

AU - Lundsgaard Hansen, Martin

AU - Fallentin, Eva

AU - Lauridsen, Carsten

AU - Law, Ian

AU - Federspiel, Birgitte

AU - Bæksgaard, Lene

AU - Svendsen, Lars Bo

AU - Nielsen, Michael Bachmann

PY - 2014

Y1 - 2014

N2 - OBJECTIVES: To evaluate whether early reductions in CT perfusion parameters predict response to pre-operative chemotherapy prior to surgery for gastroesophageal junction (GEJ) and gastric cancer.MATERIALS AND METHODS: Twenty-eight patients with adenocarcinoma of the gastro-esophageal junction (GEJ) and stomach were included. Patients received three series of chemotherapy before surgery, each consisting of a 3-week cycle of intravenous epirubicin, cisplatin or oxaliplatin, concomitant with capecitabine peroral. The patients were evaluated with a CT perfusion scan prior to, after the first series of, and after three series of chemotherapy. The CT perfusion scans were performed using a 320-detector row scanner. Tumour volume and perfusion parameters (arterial flow, blood volume and permeability) were computed on a dedicated workstation with a consensus between two radiologists. Response to chemotherapy was evaluated by two measures. Clinical response was defined as a tumour size reduction of more than 50%. Histological response was evaluated based on residual tumour cells in the surgical specimen using the standardized Mandard Score 1 to 5, in which values of 1 and 2 were classified as responders, and 3 to 5 were classified as nonresponders.RESULTS: A decrease in tumour permeability after one series of chemotherapy was positively correlated with clinical response after three series of chemotherapy. Significant changes in permeability and tumour volume were apparent after three series of chemotherapy in both clinical and histological responders. A cut-off value of more than 25% reduction in tumour permeability yielded a sensitivity of 69% and a specificity of 58% for predicting clinical response.CONCLUSION: Early decrease in permeability is correlated with the likelihood of clinical response to pre-operative chemotherapy in GEJ and gastric cancer. As a single diagnostic test, CT Perfusion only has moderate sensitivity and specificity in response assessment of pre-operative chemotherapy making it insufficient for clinical decision purposes.

AB - OBJECTIVES: To evaluate whether early reductions in CT perfusion parameters predict response to pre-operative chemotherapy prior to surgery for gastroesophageal junction (GEJ) and gastric cancer.MATERIALS AND METHODS: Twenty-eight patients with adenocarcinoma of the gastro-esophageal junction (GEJ) and stomach were included. Patients received three series of chemotherapy before surgery, each consisting of a 3-week cycle of intravenous epirubicin, cisplatin or oxaliplatin, concomitant with capecitabine peroral. The patients were evaluated with a CT perfusion scan prior to, after the first series of, and after three series of chemotherapy. The CT perfusion scans were performed using a 320-detector row scanner. Tumour volume and perfusion parameters (arterial flow, blood volume and permeability) were computed on a dedicated workstation with a consensus between two radiologists. Response to chemotherapy was evaluated by two measures. Clinical response was defined as a tumour size reduction of more than 50%. Histological response was evaluated based on residual tumour cells in the surgical specimen using the standardized Mandard Score 1 to 5, in which values of 1 and 2 were classified as responders, and 3 to 5 were classified as nonresponders.RESULTS: A decrease in tumour permeability after one series of chemotherapy was positively correlated with clinical response after three series of chemotherapy. Significant changes in permeability and tumour volume were apparent after three series of chemotherapy in both clinical and histological responders. A cut-off value of more than 25% reduction in tumour permeability yielded a sensitivity of 69% and a specificity of 58% for predicting clinical response.CONCLUSION: Early decrease in permeability is correlated with the likelihood of clinical response to pre-operative chemotherapy in GEJ and gastric cancer. As a single diagnostic test, CT Perfusion only has moderate sensitivity and specificity in response assessment of pre-operative chemotherapy making it insufficient for clinical decision purposes.

KW - Adenocarcinoma

KW - Adult

KW - Aged

KW - Esophagogastric Junction

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Neoadjuvant Therapy

KW - Prospective Studies

KW - Stomach Neoplasms

KW - Tomography, X-Ray Computed

KW - Tumor Markers, Biological

U2 - 10.1371/journal.pone.0097605

DO - 10.1371/journal.pone.0097605

M3 - Journal article

C2 - 24845062

VL - 9

SP - 1

EP - 10

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 5

M1 - e97605

ER -

ID: 138380461